Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy
Trends in Pharmacological Sciences · 2026-03 · 47 (3) · 244-247
DOI: 10.1016/j.tips.2026.01.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2026-03. Verfasst von Rajan Thapa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Western Sydney University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
- School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
- NICM Health Research Institute and School of Science, Western Sydney University, Westmead, New South Wales 2145, Australia. Electronic address: k.paudel@westernsydney.edu.au.
Förderung
- Western Sydney University
Zitieren
APA
Thapa, R., Shrestha, J., & Paudel, K. R. (2026). Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy. Trends in Pharmacological Sciences, 47(3), 244-247. https://doi.org/10.1016/j.tips.2026.01.009
Vancouver
Thapa R, Shrestha J, Paudel KR. Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy. Trends in Pharmacological Sciences. 2026;47(3):244-247. doi:10.1016/j.tips.2026.01.009
BibTeX
@article{Thapa2026,
author = {Thapa, Rajan and Shrestha, Jesus and Paudel, Keshav Raj},
title = {Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy},
journal = {Trends in Pharmacological Sciences},
year = {2026},
volume = {47},
number = {3},
pages = {244--247},
doi = {10.1016/j.tips.2026.01.009}
}
EUVIMED